CVRx (NASDAQ:CVRX) Releases Earnings Results, Misses Estimates By $0.01 EPS

CVRx (NASDAQ:CVRX) issued its earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.01), FiscalAI reports. CVRx had a negative return on equity of 152.35% and a negative net margin of 84.93%.The company had revenue of $15.71 million for the quarter, compared to the consensus estimate of $15.55 million.

Here are the key takeaways from CVRx’s conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Price Performance

CVRX stock opened at $2.97 on Tuesday. The company has a debt-to-equity ratio of 2.94, a quick ratio of 6.87 and a current ratio of 8.04. The business has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $5.69. The company has a market capitalization of $79.12 million, a P/E ratio of -1.50 and a beta of 0.76. CVRx has a 52-week low of $2.20 and a 52-week high of $11.30.

Insider Activity at CVRx

In related news, COO Brent Binkowski bought 26,223 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were bought at an average price of $2.91 per share, for a total transaction of $76,308.93. Following the completion of the acquisition, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at $164,455.74. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on CVRX shares. Wall Street Zen cut CVRx from a “hold” rating to a “sell” rating in a research note on Sunday. Lake Street Capital cut CVRx from a “buy” rating to a “hold” rating and cut their target price for the stock from $14.00 to $3.50 in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a report on Monday, August 3rd. Piper Sandler downgraded shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, August 7th. Finally, Cantor Fitzgerald decreased their price target on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating for the company in a research note on Monday, August 17th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CVRx has a consensus rating of “Hold” and an average price target of $5.30.

About CVRx

CVRx, Inc is a medical device company that develops and commercializes neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to use the body’s nervous system to help regulate cardiovascular function and address conditions that may not be adequately managed with conventional drug therapy.

CVRx’s primary product is Barostim, an implantable system that electrically stimulates the baroreceptors located near the carotid arteries. The therapy is intended to activate the body’s natural cardiovascular regulation mechanisms and is used primarily in eligible patients with heart failure, including certain patients with reduced ejection fraction.